## TOPCON CORPORATION FY2024 Q1 Financial Results

Senior Managing Executive Officer General Manager of Accounting and Finance Div. Haruhiko Akiyama July 30, 2024



# ΤΟΡΟΟΓΛ

#### **Event Overview**

Company	TOPCON CORPORATION
Event Type	Presentation of Financial Results
Event Name	FY2024 Q1 Financial Results
Report Period	FY2024 Q1
Date	July 30, 2024
Time	3:30-4:20 PM (Total: 50 minutes; Presentation: 20 minutes; Q&A: 30 minutes)
Event Format	Online (streamed)
Number of Speakers	2 Haruhiko Akiyama Director, Senior Managing Executive Officer, General Manager of Accounting & Finance Div. Takaaki Hirayama Executive Officer, Vice General Manager, Corporate Planning & Digital Business Operation Div.

lighlight of	f FY2024	Q1 Financial Results	۷
FY24 Q1 Finand	cial Results		
<u>Consolidated</u>		Positioning Business YoY	Eye Care Business
Net Sales	<b>¥51.4B</b> YoY +3%	Net Sales	Net Sales
Operating Income Net sales were flat year decreased	<b>¥0.7B</b> YoY -60% on year, but profit	Market conditions deteriorated from the original forecast, but fixed cost reductions due to structural reforms were in line with the plan	Operating Income Sales are steady, but expenses for growth investment increased
• FY24 Full Year Consolidated	Outlook	Positioning Business	Eye Care Business
• FY24 Full Year Consolidated Net Sales	Outlook ¥230.0B YoY +6%	Positioning Business YoY Net Sales	Eye Care Business YoY Net Sales
<u>Consolidated</u>	¥230.0B YoY +6% ¥18.0B	YoY Net Sales Operating Income	YoY Net Sales Operating Income
Consolidated Net Sales	<b>¥230.0B</b> YoY +6% <b>¥18.0B</b> YoY +61%	VoY Net Sales	YoY Net Sales

Financial Highlights

• FY24 Q1 Financial Results

Consolidated: Net sales were flat year on year, but profit decreased. Positioning Business: Market conditions deteriorated from the original forecast, but fixed cost reductions due to structural reforms were in line with the plan.

Eye Care Business: Despite an increase in sales, profit decreased because expenses for growth investments increased (strengthening personnel and R&D for new business development).

FY24 Full Year Outlook

Consolidated: No change from the initial plan. Increase in sales and significant increase in profit are expected.

## 01 FY24 Q1 Financial Results

- Consolidated Financial Results Overview | Positioning Business Overview | Eye Care Business • •
- •

## 02 FY24 Full Year Outlook Consolidated Full Year Outlook Qutlook | Pacific interval

- Outlook | Positioning Business Outlook | Eye Care Business
- •


## **03** Topics

- Positioning Business | Supporting the Acceleration of the spread of i-Construction through the introduction of new products Eye Care Business | Alliance with TESSAN, a French startup for remote medical care External Evaluations ٠

# 04 Appendix

- Financial Results
  Sales by Region
  Capital Expenditure, Depreciation and R&D / Forex Sensitivity

# ΤΟΡΟΟΓΛ



#### 01 | FY24 Q1 Financial Results Consolidated Financial Results

(Unit: billion ye	n)	FY2023 Q1 Actual	FY2024 Q1 Actual	YoY	%	*YoY -¥3.5B
Net Sales		49.7	51.4	+1.7	+3	< excluding FX effects
Gross Profit		26.4	27.6	+1.2	+4	
Gross Profit Rat	tio	53.1%	53.6%	+0.5pt		
SGA		24.7	26.9	+2.2	+9	
Operating Inco	me	1.7	0.7	-1.0	-60	
Operating Inco	me Ratio	3.5%	1.3%	-2.1pt		
Ordinary Incom	ne	1.8	-0.4	-2.2		
Extraordinary L	osses	-1.4	-	+1.4		
Net Income		-0.2	-1.0	-0.8		
Exchange rate	USD	¥138.11	¥156.53	¥+18.42		
(Average)	EUR	¥150.35	¥168.37	¥+18.02		

©Topcon Corporation


**Consolidated Financial Results** 

 $\cdot$  Net sales: 51.4 billion yen (+3%). However, if the FX effects the yen's depreciation are excluded, net sales decreased.

• Operating income decreased due to an increase in SG&A expenses. SG&A expenses decreased by several hundred million yen excluding the effect of FX rates.

The decrease in ordinary income was due to FX rates. FX gains were recorded in the same quarter of the previous year.

**ΤΟΡΟΟΝ** 



Operating Income YoY Breakdown

Factors behind the 1.0 billion yen decrease in profit from FY2023 Q1 results (1.7 billion yen)

Sales Volume, Product Mix effect: -2.5 billion yen. Of this, -1.4 billion yen in Positioning Business and -1.1 billion yen in Eye Care Business

Manufacturing Cost effect: +0.1 billion yen

Effect of POB structural reforms, etc.: 1.6 billion yen, more than a quarter of the planned annual 6 billion yen

Fixed Cost effect: -1.1 billion yen. Growth investment in Eye Care Business: -0.6 billion yen, other fixed costs: -0.5 billion yen

FX impact (effect): +0.9 billion yen due to the yen's depreciation In total, the FY2024 Q1 Results are 0.7 billion yen

#### 01 | FY24 Q1 Financial Results Overview | Positioning Business

• Market conditions deteriorated from the original forecast, but fixed cost reductions due to structural reforms were in line with the initial plan


/en)	FY2023 Q1 Actual	FY2024 Q1 Actual	YoY	%	*YoY -¥2.7B
	32.9	33.8	+0.9	+3	excluding F
come	1.8	1.9	+0.1	+6	
come Ratio	5.4%	5.6%	+0.2pt		
USD	¥138.11	¥156.53	¥+18.42		
EUR	¥150.35	¥168.37	¥+18.02		
		ven) Q1 Actual 32.9 come 1.8 come Ratio 5.4%	Q1 Actual      Q1 Actual        32.9      33.8        come      1.8        come Ratio      5.4%        USD      ¥138.11	Q1 Actual      Q1 Actual      YoY        32.9      33.8      +0.9        come      1.8      1.9      +0.1        come Ratio      5.4%      5.6%      +0.2pt        USD      ¥138.11      ¥156.53      ¥+18.42	Q1 Actual      Q1 Actual      YoY      %        32.9      33.8      +0.9      +3        come      1.8      1.9      +0.1      +6        come Ratio      5.4%      5.6%      +0.2pt        USD      ¥138.11      ¥156.53      ¥+18.42

Overview of the Positioning Business

Market conditions (mainly IT Agriculture-related) deteriorated from initial expectations.

Net sales were 33.8 billion yen, up 0.9 billion yen YoY, but down 2.7 billion yen excluding the effect of FX.

Operating income increased by 0.1 billion yen to 1.9 billion yen as fixed cost reductions due to structural reforms were in line with the plan.



Overview of Positioning Business

(Previously, we explained the situation in each region based on products and solutions. From this presentation forward, the explanation will be based on regions)

North America: 14.5 billion yen (+1.5 billion yen YoY)

Europe: 9.7 billion yen (+1.3 billion yen YoY)

Japan: 5.2 billion yen (-1.0 billion yen YoY)

Asia/Oceania/Others: 4.3 billion yen (-0.9 billion yen YoY)

Main reasons for the increase/decrease in each region

North America: ICT Construction was showing signs of a recovery mainly in the aftermarket due to the stabilization of market inventories (distributors' inventories) and infrastructure demand. On the other hand, IT Agriculture sales decreased as lower grain prices curbed investment.

Europe: IT Agriculture sales decreased as lower grain prices curbed investment. The new consolidation of the acquired Satel contributed to increased sales (consolidated from June 2023).

Japan: ICT Construction is steady, particularly for Kui-Navi shovel. IT Agriculture continues to be impacted by the loss of subsidies, etc. Sales of Surveying instruments temporarily decreased owing to inventory adjustments in the market.


#### 01 | FY24 Q1 Financial Results Overview | Eye Care Business

 Sales are steady, but expenses for growth investment (Strengthening personnel and R&D for new business development) increased

Net Sales Operating Income Operating Income Ratio	16.6 1.1 6.4%	17.6 0	+1.0	+6
		0	-1.0	
Operating Income Ratio	C 10/			
	0.4%	0.1%	-6.3pt	
Exchange rate USD	¥138.11	¥156.53	¥+18.42	
(Average) EUR	¥150.35	¥168.37	¥+18.02	

### Eye Care Business

Sales were 17.6 billion yen, up 1.0 billion yen YoY, but down 0.6 billion yen excluding the effect of FX, mainly due to a decline of sales in China. Operating income decreased by 1.0 billion yen to 0 billion yen due to increased expenses for growth investment, such as the reinforcement of personnel and R&D for new business development.



#### Sales of Eye Care Business by Region


(As with the Positioning Business, we previously explained the status of each region based on products and solutions. From this presentation onward, the explanation will be based on regions) North America: 4.6 billion yen (+0.3 billion yen YoY) Europe: 4.9 billion yen (+0.4 billion yen YoY) Japan: 2.4 billion yen (+0.1 billion yen YoY) Asia and Oceania: 5.7 billion yen (+0.2 billion yen YoY)

Main reasons for the increase/decrease in each region

North America: Solid sales continued, mainly to major optical chain stores. While streamlining the sales company, the sales organization was reorganized and reinforced.

Europe: Sales continued to be strong, mainly to major optical chain stores. Sales of fundus cameras were strong, including the acquisition of large orders.

Asia & Oceania: Sales in China declined sharply due to tight local government finances and anti-corruption campaigns. Sales in India and Southeast Asia increased due to the continuous acquisition of tender projects, etc.



#### 02 | FY24 Full Year Outlook Consolidated Full Year Outlook

#### • No change from the initial plan

(Unit: billion ye	n)	FY2023 Actual	FY2024 Outlook	YoY	%	
Net sales		216.5	230.0	+13.5	+6	
Operating inco	me	11.2	18.0	+6.8	+61	
Ordinary incom	ie	8.9	15.5	+6.6	+75	
Net income		4.9	9.5	+4.6	+92	
ROE		5%	9%	+4pt		
Dividend		¥42	¥42	0	0	
Dividend payou	ut ratio	90%	47%	-43pt		
Exchange rate	USD	¥144.40	¥145.00			
(Average)	EUR	¥156.80	¥155.00			
			Assumption rate of Q2 onward			
		©Topcon C	orporation			🚝 ТОР

Consolidated

No change from the outlook at the beginning of the period (no change from sales to dividends)

The following pages detail the outlook for each business segment.

Net sales  140.4  147.0  +6.6  +5    Operating income  9.1  16.5  +7.4  +81    Operating Income Rate  6.5%  11.2%  +4.7pt    Exchange rate    USD  ¥144.0  ¥145.00	(Unit: billion yen)	FY2023 Actual	FY2024 Outlook	YoY	%
Use      Use      Harmonic      Harmo	Net sales	140.4	147.0		
Exchange rate USD ¥144.40 ¥145.00	Operating income	-			+81
Exchange rate	Operating Income Rate	6.5%	11.2%	+4.7pt	
Exchange rate					
	Exchange rate	¥144.40	¥145.00		
(Average) EUR ¥156.80 ¥155.00	(Average) EUR	¥156.80	¥155.00		

No change in the outlook for the Positioning Business

It is expected that sales will increase due to strategic new product launches in and after Q2 stimulating demand.


It is expected that profitability will improve due to the effects of structural reforms


		FY2023	FY2024		
(Unit: billion	yen)	Actual	Outlook	YoY	%
Net sales		75.2	82.0	+6.8	+9
Operating in	come	6.7	7.5	+0.8	+12
Operating In	come Rate	8.9%	9.1%	+0.2pt	
Exchange rate (Average)	EUR	¥144.40 ¥156.80	¥145.00 ¥155.00		
			Assumption rate of Q2 onward		

No change in the outlook for the Eye Care Business

The strong Screening Business and new product launches will accelerate the growth of revenue.

Operating income is expected to increase despite continued investment in growth, but expenses are expected to increase due to higher sales.





Positioning Business Topics

Supporting the acceleration of i-Construction through the introduction of new products

We will support the in-house production of 3D data acquisition and the creation of 3D data, which has been a bottleneck in the spread of i-Construction.

We released Men-Toru, an easy-to-operate, low-cost 3D laser scanner based on our "Measurement Technology", and TopModeler 3D, which is 3D design data conversion software.

In the past, the 3D ground surveying, 3D design data creation and 3D formwork management processes for the introduction of new products were outsourced to outside specialists.

Our products enable the centralized management of the construction process.

03 | Topics | Eye Care Business Alliance with TESSAN, a French startup for remote medical care Lack of Ophthalmologists in France causing long wait times for eyeglass prescriptions Promoting efficiency through remote medical examinations using our fully-automated testing equipment Currently, the service is mainly offered in France, but will be expanded to other European countries TESSAN's Business Our fully-automated testing equipment General purchase period for glasses Completes testing in approximately in France: 90 days 10 minutes Reduced to 3-5 days (iii) Purchase glasse i) Web reservations (ii) Go to an optical store, have an immediately after the 3-5 days in advance eye exam remotely, and receive a eye exam prescription Topcon's fully-automated inspection equipment is used to Previously, clients had to wait 90 days or more to see an ophthalmologist and get a prescription. perform eye exams in approximately 10 minutes By using TESSAN's services, clients can purchase glasses with a 3-5 day advance reservation at the TESSAN remote medical care station ©Topcon Corporation

Eye Care Business Topics

Alliance with TESSAN, a French startup for remote medical care In France, glasses are made after a customer visits an ophthalmologist and gets a prescription. There is a shortage of ophthalmologists, and the waiting time for eyeglass prescriptions is long. It takes more than 90 days to purchase eyeglasses.

A startup for remote medical care, TESSAN offers a solution to shorten this period.

• Increased efficiency by utilizing our fully-automated inspection equipment. • Reduced eyeglass purchase time to 3-5 days. Currently, the service is being offered mainly in France, but will be expanded to other European countries.

#### 03 | Topics External Evaluations

 Selected as one of DX Platinum Companies 2024-2026 and a component of MSCI NIHONKABU ESG Select Leaders Index for its digital transformation and sustainability initiatives, respectively



#### External evaluations

Our commitment to digital transformation and sustainability initiatives has earned us recognition as one of the DX Platinum Companies for 2024-2026 and inclusion in the MSCI NIHONKABU ESG Select Leaders Index.

#### (Reference)

DX Stocks: The DX Stocks program selects companies listed on the Tokyo Stock Exchange that have established internal mechanisms to promote DX increasing corporate value and that have demonstrated outstanding achievements in the use of digital technology. The objective is to further promote DX by evaluating and widely disseminating information about model corporations to a wide range of stakeholders.


Companies selected as DX Stocks have not only introduced superior information systems and utilized data, but also continue to boldly take on the challenge of transforming their business model and management using digital technology.


In addition, to strongly encourage DX initiatives that contribute to strengthening the competitiveness of companies, the DX Grand Prix Companies were announced. Selected from among the DX Stocks companies, they are companies leading the digital age. Additionally, companies that continue their particularly outstanding efforts will be selected as DX Platinum Companies 2024-2026.


#### 03 | Topics **External Evaluations** Selected as one of DX Platinum Companies 2024-2026 and a component of MSCI NIHONKABU ESG Select Leaders Index for its digital transformation and sustainability initiatives, respectively Selected as one of DX Platinum Companies 2024-2026 New Selected as a component of MSCI New NIHONKABU ESG Select Leaders Index DXプラチナ企業 2024-2026 Digital Transformation 2024 CONSTITUENT MSCI NIHONKABU FTSE Blossom 5 ESG SELECT LEADERS INDEX Japan Sector Relative Index \*1 FTSE Blossom Japan Sector Relative Index In DX Stocks 2024 selected by The Selected as a component of the MSCI Ministry of Economy, Trade and Industry, Japan ESG Select Leaders Index. the Tokyo Stock Exchange, and the which covers domestic stocks adopted Information-technology Promotion by Japan's Government Pension M**ANINESTAR** GenDi J Agency, following last year's DX Grand Investment Fund (GPIF) Japon ex Re T Gonder Dive Titlindes Prix award, selected as one of DX Platinum Companies 2024-2026 · The MSCI Japan ESG Select Leaders Index is an index \*2 S&P/JPX on Efficient Index \*3 Morningstar Gender Diversity Index constructed by selecting companies that excel in ESG evaluations provided by Morgan Stanley Capital Selection criteria International (MSCI) of the United States Selected as a DX Stock for three consecutive years Topcon has already been selected as a component of the ESG index (\*1, \*2, \*3) listed on the right, which cover domestic stocks adopted by the GPIF (achieved in 2021-2023) Selected as DX Grand Prix in the past (achieved in IR Site 2023) BRONZE ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES ADDEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES ©Topcon Corporation **TOPCON** 20


MSCI NIHONKABU ESG Select Leaders Index: An index developed by USbased Morgan Stanley Capital International (MSCI) that selects companies highly rated in terms of ESG. It is one of six ESG indexes of domestic stocks used by Japan's Government Pension Investment Fund (GPIF).

















## Cautionary Note regarding Forward-Looking Statements

These materials contain forward-looking statements, including projections of future operating performance. Such statements are based on management's best judgment, given the materials available to them at the time these statements are made. However, please be aware that actual performance may differ from projected figures owing to unexpected changes in the economic environment in which we operate, as well as to market fluctuations.

The original disclosure in Japanese was released on July 30, 2024 at 15:00(JST)

Inquiries

Corporate Planning & Digital Business Operation Div. Corporate Communication Dept. TOPCON CORPORATION Tel: +81-3-3558-2532 E-mail: investor\_info@topcon.co.jp URL: https://global.topcon.com/invest/

# ΤΟΡΟΟΓΛ